Skip to main content
. 2020 Dec 22;13(1):3. doi: 10.3390/cancers13010003

Table 1.

Patients’ baseline characteristics in the training and validation cohorts.

Demographic or Characteristic Training Cohort
(N = 4154)
Validation Cohort
(N = 5161)
p Value
Age (year) a 59.3 ± 11.65 58.5 ± 11.95 0.850
<60 2103 (50.6) 2645 (51.2) 0.549
≥60 2051 (49.4) 2516 (48.8)
Gender b 0.804
Male 2454 (59.1) 3062 (59.3)
Female 1700 (40.9) 2099 (40.7)
BMI (kg/m2) b -
<24 1828 (44.0) -
≥24 1383 (33.3) -
Hypertension b -
No 3554 (85.6) -
Yes 600 (14.4) -
Diabetes mellitus b -
No 3842 (92.5) -
Yes 312 (7.5) -
Tumor location b 0.005
Right colon 899 (21.6) 1220 (23.7)
Transverse colon 85 (2.0) 110 (2.1)
Left colon 256 (6.2) 362 (7.0)
Sigmoid colon 721 (17.4) 773 (15.0)
Rectum 2193 (52.8) 2696 (52.2)
Tumor diameter b <0.001
<50 mm 1640 (39.5) 3446 (66.8)
≥50 mm 2359 (56.8) 1710 (33.1)
Pathological classification b <0.001
Prominence 2740 (66.0) 1277 (24.7)
Infiltration 268 (6.4) 238 (4.6)
Ulceration 160 (3.9) 3436 (66.6)
Infiltration and ulceration 986 (23.7) 210 (4.1)
Differentiation degree b <0.001
Well 331 (8.0) 48 (0.9)
Moderate 3225 (77.6) 3755 (72.8)
Poor 598 (14.4) 1358 (26.3)
Histologic classification b <0.001
Adenocarcinoma 3136 (75.5) 4342 (84.1)
Mucinous adenocarcinoma + signet ring cell carcinoma 1018 (24.5) 819 (15.9)
TNM staging b <0.001
II 2385 (57.4) 2086 (40.4)
III 1769 (42.6) 3075 (59.6)
AJCC staging II b <0.001
IIA 974 (40.8) 1175 (56.3)
IIB 180 (7.6) 882 (42.3)
IIC 1231 (51.6) 29 (1.4)
AJCC staging III b <0.001
IIIA 122 (6.9) 271 (8.8)
IIIB 752 (42.5) 1727 (56.2)
IIIC 895 (50.6) 1077 (35.0)
Tumor invasion b <0.001
T1–T3 1847 (44.5) 2588 (50.1)
T4 2307 (55.5) 2573 (49.9)
Lymph nodes involved b <0.001
N0 2385 (57.4) 2086 (40.4)
N1–N2 1769 (42.6) 3075 (59.6)
Cancer nodules b <0.001
No 3863 (93.0) 4249 (82.3)
Yes 291 (7.0) 912 (17.7)
Nerve invasion b <0.001
No 3836 (92.3) 3898 (75.5)
Yes 318 (7.7) 1263 (24.5)
Vascular tumor thrombus b <0.001
No 4009 (96.5) 3622 (70.2)
Yes 145 (3.5) 1539 (29.8)
CEA b 0.971
<5 ng/mL 2203 (53.0) 2832 (54.9)
≥5 ng/mL 1626 (39.1) 2087 (40.4)
CA19-9 b <0.001
<37 U/mL 3026 (72.8) 3932 (76.2)
≥37 U/mL 621 (14.9) 991 (19.2)
Postoperative chemotherapy b <0.001
No 2413 (58.1) 940 (18.2)
Yes 1741 (41.9) 4221 (81.8)
Postoperative radiotherapy b <0.001
No 3969 (95.5) 4752 (92.1)
Yes 185 (4.5) 409 (7.9)
Platelet counts (109/L) c 247 (204–305) 232 (189–283) <0.001
Neutrophil counts (109/L) c 3.77 (2.95–4.83) 3.50 (2.80–4.50) <0.001
Lymphocyte counts (109/L) c 1.89 (1.50–2.34) 1.70 (1.30–2.10) <0.001
Monocyte counts (109/L) c 0.43 (0.33–0.54) 0.40 (0.30–0.50) <0.001
Eosinophil counts (109/L) c 0.12 (0.06–0.20) 0.13 (0.08–0.22) <0.001
Basophil counts (109/L) c 0.04 (0.02–0.06) 0.02 (0.01–0.04) <0.001

Abbreviations: BMI, body mass index; AJCC, American Joint Committee on Cancer; Data are presented as a mean (standard deviation), b n (%) or c median (interquartile ranges). The validation cohort did not contain BMI and history of hypertension and diabetes. The number of missing values for BMI, tumor diameter, CEA, and CA19-9 were 943, 155, 325 and 507, respectively, in the training cohort. The number of missing values for tumor diameter, CEA, and CA19-9 were 5, 242 and 238, respectively, in the validation cohort.